Potential Value of Immunohistochemical Expression of SOX17 and E-Cadherin in Variable Endometrial Lesions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-12-31

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Endometrial carcinoma (EC) is the 6th most commonly occurring cancer in women and the 15th most common cancer overall According to facts derived from Globocan for the year 2020.The overall incidence was 417,367 and 97,370 died due to it. There were more than 417,000 new cases of endometrial cancer in 2020 .EC incidence is predicted to continue to rise in the coming decades, in particular among low and middle-income countries.

SOX17 protein (SRY-box 17) is a member of the SRY-related HMG-box (SOX) family of transcription factors that controls the first step of gene expression and regulates cellular growth and differentiation in the endoderm, during hematopoiesis, and in the cardiovascular system E-Cadherin is a calcium-dependent cell adhesion protein (predicted molecular weight of 97 kDa) that plays a vital role in cell migration and proliferation. The E-cadherin epithelial cell adhesion protein is a tumor suppressor that has an important role in tumor metastasis The loss of expression of E-Cadherin during the epithelial mesenchymal transition (EMT) is often thought to promote metastasis by allowing the dissociation and invasion of cancer cells

The aim of this study is:

1. To evaluate accuracy of SOX17 expression in neoplastic and hyperplastic endometrial lesions.
2. To correlate SOX17 expression with some clinical and pathological parameters of endometrial carcinoma.
3. To evaluate E-Cadhrin expression and its relation to SOX17 in neoplastic and hyperplastic lesions

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

the Value of Immunohistochemical Expression of Moesin in Endometrial Hyperplasia and Endometrial Carcinoma

NCT05619159

Endometrial Cancer and Endometrial Hyperplasia

UNKNOWN

Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma

NCT05273099

Cancer of Endometrium

UNKNOWN

Disseminated Endometrial Cancer Cells During Sonohysterography

NCT00205023

Endometrial Cancer

COMPLETED NA

Clinicopathological Analysis of Endometrial Carcinoma in the View of Old and New International Federation of Gynecology and Obestetrics (FIGO)

NCT06632431

Clinicopathological Endometrial Carcinoma Federation of Gynecology and Obestetrics

RECRUITING

Human Epididymis Protein 4 in Endometrial Carcinoma

NCT03456791

Endometrial Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Variable Endometrial Lesions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Specimens of total abdominal hysterectomy and bilateral salpingio-oopherectomy of endometrial carcinoma patients 2. D\&C of endometrial tissue suspected of hyperplastic or neoplastic lesions